Sarepta Therapeutics (SRPT) announced AdCom to be held for SRP-9001
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Sarepta (SRPT) sinks 20% as surprise FDA AdComm for SRP-9001 adds risk
March 17, 2023 6:52 AM EDTShares of Sarepta Therapeutics (NASDAQ: SRPT) fell 20% in pre-open trading Friday after the company announced a surprise FDA AdComm for SRP-9001, its investigational gene therapy for the treatment of Duchenne muscular dystrophy. The news comes just a few weeks after management indicated that there would be no AdComm.
While the news adds a layer of risk, most analysts still expected FDA approval at the May 29th PDUFA date.
"FDAs decision to hold a public advisory committee meeting on the SRP 9001 BLA is a change from the communicated... More
